Health Dictionary Find a Doctor

Steatorrhea pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Sunny Kumar MD [2]

Overview

Steatrorhea can be defined as loss of undigested fat in stools. The processes can be invoked by either defect of the normal architecture of digestive tract or it may involve defect of synthesis or secretion of enzymes of GI tract which are needed to metabolize fatty content of food.

Pathophysiology

Normal Fat absorption

To understand the pathophysiology of fat malabsoption we need to understand normal physiology of fat metabolization:[1][2][3][4][5][6][7][8]

Pathogenesis

Any disturbance in the normal physiology results in decreased absorption of the fats.

Genetics:

The development of steatorrhea is the result of multiple genetic mutations. Common genetic conditions associated with steatorrhea include:

Gross pathology

On gross pathology the gastro-intestinal tract looks normal in conditions which involves enzyme deficiencies. However in condition which involves obstruction of ducts involved in secretion of enzymes will look narrowed. The luminal causes which damage the luman of GIT and does not allow the absoption of faty products will also look ulcerated.

Microscopic pathology

On microscopy the GIT looks normal in conditions which involves enzyme deficiencies. However in condition which involves obstruction of ducts involved in secretion of enzymes will look narrowed. The luminal causes which damage the luman of GIT and does not allow the absoption of faty products will also look ulcerated.

References

  1. Kumar R, Bhargava A, Jaiswal G (2017). “A case report on total pancreatic lipomatosis: An unusual entity”. Int J Health Sci (Qassim). 11 (4): 71–73. PMC 5654180. PMID 29085272.
  2. Previti E, Salinari S, Bertuzzi A, Capristo E, Bornstein S, Mingrone G (2017). “Glycemic control after metabolic surgery: a Granger causality and graph analysis”. Am J Physiol Endocrinol Metab. 313 (5): E622–E630. doi:10.1152/ajpendo.00042.2017. PMID 28698280.
  3. Vakhrushev YM, Lukashevich AP (2017). “[Specific features of impaired intestinal digestion, absorption, and microbiocenosis in patients with cholelithiasis]”. Ter Arkh. 89 (2): 28–32. doi:10.17116/terarkh201789228-32. PMID 28281512.
  4. Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG Group. Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners (2016). “Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression”. BMC Med. 14 (1): 179. doi:10.1186/s12916-016-0718-z. PMC 5101793. PMID 27825371.
  5. Podboy A, Anderson BW, Sweetser S (2016). “61-Year-Old Man With Chronic Diarrhea”. Mayo Clin Proc. 91 (2): e23–8. doi:10.1016/j.mayocp.2015.07.033. PMID 26769182.
  6. Burnett JR, Hooper AJ (2015). “Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemia”. Free Radic Biol Med. 88 (Pt A): 59–62. doi:10.1016/j.freeradbiomed.2015.05.044. PMID 26086616.
  7. Valenzise M, Alessi L, Bruno E, Cama V, Costanzo D, Genovese C; et al. (2016). “APECED syndrome in childhood: clinical spectrum is enlarging”. Minerva Pediatr. 68 (3): 226–9. PMID 25502918.
  8. Wilcox C, Turner J, Green J (2014). “Systematic review: the management of chronic diarrhoea due to bile acid malabsorption”. Aliment Pharmacol Ther. 39 (9): 923–39. doi:10.1111/apt.12684. PMID 24602022.

Template:WS Template:WH

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH